Xofluza 40 mg, Filmtabletten - Swissmedic Key 67426003 Registration Holder Roche Pharma (Schweiz) AG Name Xofluza 40 mg, Filmtabletten Date of registration 19.02.2020 Introduction of Sequence 19.02.2020 ATC-Classification Baloxavir Marboxil (J05AX25) Revision date WHO WHO-DDD Valid until Index Therapeuticus (BSV) Show package size Index Therapeuticus (Swissmedic) 08.03. Description Swissmedic categorie. B SL Eintrag No Indication Information for professionals IP Consumer information CI Deductible k.A. Feedback FB GTIN 7680674260035 Medication Code Synthetika Pharmacode Disponibility
Composition baloxavirum marboxilum 40 mg, lactosum monohydricum 155.8 mg, carmellosum natricum conexum, povidonum K 25, cellulosum microcristallinum, natrii stearylis fumaras, talcum, Überzug: hypromellosum, talcum, E 171, pro compresso obducto corresp. natrium 2.26 mg. Packungsbestandteile Galenic Form Coated tablets Active Agent Dose Baloxavirum Marboxilum 40 mg
Inactive agents Dose additional_information Carmellosum Natricum Conexum Cellulosum Microcristallinum E 171 color. Hypromellosum Überzug Lactose Monohydrate 155.8 mg Natrii Stearylis Fumaras Povidonum K 25 Pro Compresso Obducto Talcum
Source Data was imported : 05.09.2025
Swissmedic Registration :
Sequence :
Product name :
Registration owner: :
Product group :
Index Therapeuticus (BSV) :
Medication Code :
Date of registration :
Valid until :
Package number :
Show package size :
Commercial Form/Unit :
Swissmedic categorie. :
Active Agents :
Composition :
